Revagenix Inc
Dba Revagenix Inc
CAGE Code: 8B1Y9
NCAGE Code: 8B1Y9
Status: Active
Type: Commercial Supplier
Summary
Revagenix Inc, Dba Revagenix Inc is an Active Commercial Supplier with the Cage Code 8B1Y9.
Address
1729 Dolan Ave
San Mateo CA 94401-2126
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Cypress Pest Systems Inc Leapfrog Technologies Inc Rdc Networks Inc Desktop Photogrammetry Inc More, Inc. Get Real Labs, Inc Touch Tone Solutions Inc Fawcette Technical Publications Radio Mail Corp Tosoh Medics Inc Genomyx Corp Intellex Projection Systems National Safety Security Western Otari Corp Connectix Corp Lyons Associates Mage Corp Austin-Hayne Corporation Corsoft Corp
Frequently Asked Questions (FAQ) for CAGE 8B1Y9
- What is CAGE Code 8B1Y9?
- 8B1Y9 is the unique identifier used by NATO Organizations to reference the physical entity known as Revagenix Inc Dba Revagenix Inc located at 1729 Dolan Ave, San Mateo CA 94401-2126, United States.
- Who is CAGE Code 8B1Y9?
- 8B1Y9 refers to Revagenix Inc Dba Revagenix Inc located at 1729 Dolan Ave, San Mateo CA 94401-2126, United States.
- Where is CAGE Code 8B1Y9 Located?
- CAGE Code 8B1Y9 is located in San Mateo, CA, USA.
Contracting History for CAGE 8B1Y9 Most Recent 25 Records
- 75N93022C00061
- A Novel Lpxc Inhibitor With Pan-Resistant Pseudomonas And Burkholderia Activity.
- 22 Sep 2022
- A Novel Lpxc Inhibitor With Pan-Resistant Pseudomonas And Burkholderia Activity.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $4,798,925.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 3 Nov 2022
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,376,688.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 6 Mar 2023
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $17,497,728.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 13 Jan 2023
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $17,497,728.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 2 Dec 2022
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,376,688.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 27 Jun 2023
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $17,497,728.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 19 Jul 2022
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,376,688.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 29 Mar 2022
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,993,818.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 12 Jul 2021
- To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,714,249.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00018
- Eo14042 - To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- 14 Oct 2021
- Eo14042 - To Select A Novel Small Molecule Antibiotic For Clinical Development And Advance It Through Ind Filing And Phase 1 Clinical Studies.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,993,818.00
- Department Of Health And Human Services (Hhs)